In a survey of key opinion leaders (KOLs), 94% agreed that scientific exchange between clinical experts and biopharmaceutical companies is becoming more important. While this is positive for medical affairs, resources don’t always go hand in hand with demand. As the global head of medical affairs excellence at a top 20 biopharma acknowledged at the Veeva Commercial Summit, … [Read more...]
86% of KOLs Satisfied with Biopharma, But Cross-Functional Gaps Remain
With highly regarded field medical relationships, there is an opportunity for improvement A recent Veeva industry report shows that 86% of key opinion leaders (KOLs) are satisfied overall (74% satisfied, 12% very satisfied) when engaging with the biopharma industry. They appreciate their interactions with field medical teams and cite alignment and coordination across … [Read more...]
Bridging the Silo: The Benefits of Collaborative Medical and Commercial Partnerships
You’re meeting with a customer, and they tell you a colleague of yours was just there to discuss a similar topic. While this can catch an MSL off guard, it can also hinder your ability to further your relationship with an important key opinion leader (KOL). In a world of increasing scientific complexity and limited access, collaboration between medical, commercial, and R&D … [Read more...]
Seven Ways to Measure Medical’s Modern Strategic Value
With over 90% of KOLs looking to medical teams as partners in achieving the best patient outcome, now is the time to measure strategic influence With continued investment and innovation boosting therapeutic options available for niche diseases, staying up to date on the latest scientific evidence and guidelines remains a challenge for healthcare professionals (HCPs) and … [Read more...]
Three Ways to Improve Your KOL Engagement Strategy
Pre-Launch Field Medical Education Leads to 1.5x Increase in Treatment Adoption The Veeva Pulse Field Trends Report includes an analysis of over 600 million HCP interactions and activities from more than 80% of commercial biopharma field teams worldwide, the largest industry benchmark of its kind on HCP engagement. The recent report shares for the first time for the … [Read more...]
From Vision to Value: True Omnichannel in Field Medical
From Vision to Value: True Omnichannel in Field Medical A customer-centric approach to engagement is critical as scientific complexity grows Personalized medicines now account for more than a quarter of the new drugs approved in the past seven years(1). Oncology will be close to 20% of biopharmaceutical sales in 2024(2). Cell and gene therapies are taking center stage, … [Read more...]